Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
about
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT studyIncidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritisAutoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the LiteratureBiologics registers in RA: methodological aspects, current role and future applications.Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia.Malignant lymphomas and autoimmunity-a single center experience from Hungary.TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review.Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.Summary of worldwide pediatric malignancies reported after exposure to etanercept.Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancerA practical approach to monitoring patients on biological agents for the treatment of psoriasisMalignancy validation in a United States registry of rheumatoid arthritis patients.The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.Update on the treatment of ankylosing spondylitis.Do inflammatory bowel disease therapies cause cancer?Etanercept in the treatment of rheumatoid arthritisThe risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations.Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromesRisk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies.Treating rheumatic patients with a malignancy.Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et alObservational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and resultsSwedish registers to examine drug safety and clinical issues in RA.Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control studyRheumatoid Arthritis as a Therapeutic Challenge in a Patient with Lynch Syndrome.Clinical usefulness of blood metal measurements to assess the failure of metal-on-metal hip implantsAdalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.Acute myeloid leukemia developing in patients with autoimmune diseases.Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist.TNFalpha blockade in human diseases: an overview of efficacy and safety.Medical conditions and risk of adult myeloid leukemia.Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin's lymphoma: a Danish population-based cohort study.Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer.A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis.
P2860
Q24674942-DFA9018E-A306-4E75-9C45-D4265DDFAA23Q24675306-B35C4A93-22C7-4A61-A4AF-C555903284C2Q26739361-AC419273-25B2-49B8-B742-99146CF0D06CQ30047634-FFD5D28E-71A5-488A-BDAD-3044B4776E32Q30234303-C1A24391-736F-447B-BBE3-34D8AA6250EAQ33346685-E2462851-F7BF-41FB-BA21-D468DF58BD62Q33372701-74F16323-1193-439F-A9A6-7AFEE2FCE39DQ33396131-34A47E3A-EA5A-4565-8A18-B53E5C563D10Q33626895-9A6DFCC9-116A-4BEF-8862-9E7F6C4D801CQ33799604-DA9F3F2A-468A-440F-A264-82BB3F7D9F2AQ33973884-0D58148C-AD47-4F27-B580-249BE4FCC03BQ33997625-5E3A9870-E346-4193-9512-08D80A5776C2Q33998050-282FBA7B-C598-4768-9C62-70CD89FC59EFQ34000467-251D8C44-1504-4C58-A2DF-9545E5CB2986Q34156420-22143AC1-DAF5-40E0-95C3-6EDAE6278D86Q34287960-64D9791C-A8A4-4C30-BD25-949287F29FB1Q34363241-3EC68E27-52C9-45AB-BDDD-69C78732A4B1Q34592673-A9DF0236-2887-47AB-8CA6-592B0DA65546Q34613890-6583C056-F715-4695-8BF2-C5E1FD9B4215Q34764213-89F71418-20BF-4F99-9BAB-9174F7066BDBQ34984568-F30EFB99-C785-46A5-8E78-69F0C56966B2Q35026302-B59CBAA7-ADEA-4995-A3C0-8C3B8B183A2FQ35026464-5EB656F4-1D84-4CE1-BD33-1BFBA1D6E285Q35112330-E1E41271-740A-457A-9210-A90B1A7951FCQ35120199-E047C920-B632-4BEC-8BB1-AD13919BCA46Q35557863-E608FD2E-B962-4571-A457-8F81289EED0BQ35605656-5FB123BF-7700-4F89-BE6D-241F37EB454AQ35621627-B49820CA-1FC9-4DDA-B230-E0B3EF6FA34EQ35637262-5A419BA7-B592-45C1-B21E-DAEBB632F915Q35637884-E7270848-A0BE-47F4-A4CA-DB7BDE049082Q35827560-8282307A-2C46-48D2-A0ED-934EFBC5F43FQ35923890-637681A1-358F-4CB5-B131-3ADBDACF30AEQ35953319-2B7F29AA-79FD-4C55-A646-D92CBFBF155AQ36006358-E193DCB5-95F8-4924-972D-F2A671A99FD9Q36299952-9EE10778-675E-478F-8236-EA26E00B439EQ36536861-83DA11F2-47CF-4065-9B3C-40A685A5CCC1Q36608364-5BDA606D-C07E-4697-9434-F0B5B8D90D21Q36614643-52754C39-8027-4C35-B853-F28660C6494FQ36738727-04738719-86F1-46A1-8E8E-43BDF926B3C8Q36757029-470F91CA-5231-444A-AD7F-2A3375B21687
P2860
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Haematopoietic malignancies in ...... r necrosis factor antagonists.
@ast
Haematopoietic malignancies in ...... r necrosis factor antagonists.
@en
type
label
Haematopoietic malignancies in ...... r necrosis factor antagonists.
@ast
Haematopoietic malignancies in ...... r necrosis factor antagonists.
@en
prefLabel
Haematopoietic malignancies in ...... r necrosis factor antagonists.
@ast
Haematopoietic malignancies in ...... r necrosis factor antagonists.
@en
P2093
P2860
P356
P1476
Haematopoietic malignancies in ...... r necrosis factor antagonists.
@en
P2093
Baecklund E
Bertilsson L
Feltelius N
Jacobsson LT
P2860
P304
P356
10.1136/ARD.2004.033241
P407
P577
2005-04-20T00:00:00Z